Viatris Specialty LLC

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 4 drugs with upcoming expirations

Activity

Key Events

Dec 16, 2025FDAViagra — VYBRIQUE

Jul 24, 2025FDANorvasc — SDAMLO

Apr 25, 2025FDANeurontin — NEURONTIN

Jul 12, 2024FDANeurontin — NEURONTIN

4 more events

Dec 29, 2023TrialStudy of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy

Dec 29, 2023TrialStudy of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy

Jul 27, 2021TrialStudy Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users

Apr 30, 2021TrialStudy Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

9 patent groups across drugs · Source: FDA Orange Book

DrugExpires

TobrexSep 12, 2028 NitrostatMar 12, 2029 TobrexNov 4, 2030 NitrostatMar 11, 2032 ViagraDec 16, 2033 Norvasc13 patentsOct 6, 2037 Viagra5 patentsDec 24, 2038 NorvascApr 11, 2039

1 more

Norvasc6 patentsFeb 24, 2041

Regulatory

Regulatory Timeline

20172 events

FDAOct 18

Neurontin — NEURONTIN

Application NDA021129

FDAOct 18

Neurontin — NEURONTIN

Application NDA020882

20191 event

FDAJul 8

Norvasc — KATERZIA

Application NDA211340 (NDA)

20206 events

FDADec 16

Neurontin — NEURONTIN

Application NDA021129

FDADec 16

Neurontin — NEURONTIN

Application NDA020235

FDADec 16

Neurontin — NEURONTIN

Application NDA020882

FDAApr 2

Neurontin — NEURONTIN

Application NDA020882

FDAApr 2

Neurontin — NEURONTIN

Application NDA021129

FDAApr 2

Neurontin — NEURONTIN

Application NDA020235

20211 event

FDAOct 4

Zoloft — SERTRALINE HYDROCHLORIDE

Application NDA215133 (NDA)

20221 event

FDAFeb 24

Norvasc — NORLIQVA

Application NDA214439 (NDA)

20231 event

FDAApr 28

Viagra — LIQREV

Application NDA214952 (NDA)

20243 events

FDAJul 12

Neurontin — NEURONTIN

Application NDA020235

FDAJul 12

Neurontin — NEURONTIN

Application NDA021129

FDAJul 12

Neurontin — NEURONTIN

Application NDA020882

20255 events

FDADec 16

Viagra — VYBRIQUE

Application NDA210858 (NDA)

FDAJul 24

Norvasc — SDAMLO

Application NDA219531 (NDA)

FDAApr 25

Neurontin — NEURONTIN

Application NDA020235

FDAApr 25

Neurontin — NEURONTIN

Application NDA020882

FDAApr 25

Neurontin — NEURONTIN

Application NDA021129

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)